Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Jens Gerwien"'
Autor:
Blanca Hernández-Cruz, Uta Kiltz, Jérôme Avouac, Tamas Treuer, Ewa Haladyj, Jens Gerwien, Chandreyee Dutta Gupta, Fabrizio Conti
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1417-1457 (2023)
Abstract Introduction Baricitinib, an orally available small-molecule inhibitor of Janus kinase (JAK)1 and JAK2, is indicated to treat active moderate-to-severe rheumatoid arthritis (RA). Objective This systematic review described the real-world clin
Externí odkaz:
https://doaj.org/article/9dea967ec8f74009a3c381369d954236
Autor:
Rieke Alten, Gerd R. Burmester, Marco Matucci-Cerinic, Jean-Hugues Salmon, Andrew Östör, Khai Jing Ng, Jens Gerwien, Liliana Zaremba-Pechmann, Alan J. M. Brnabic, Bruno Fautrel
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1575-1595 (2023)
Abstract Introduction RA-BE-REAL is a 3-year, multinational, prospective, observational study of adult patients with rheumatoid arthritis (RA) evaluating time to discontinuation of initial RA treatment along with patient baseline characteristics. Thi
Externí odkaz:
https://doaj.org/article/63d5ff311b2441d18921c0a0894d1ffb
Autor:
Tue W. Kragstrup, Thomas Andersen, Line D. Heftdal, Malene Hvid, Jens Gerwien, Pallavur Sivakumar, Peter C. Taylor, Ladislav Senolt, Bent Deleuran
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
This review describes the IL-20 family of cytokines in rheumatoid arthritis (RA) and spondyloartrhitits (SpA) including psoriatic arthritis. The IL-20 receptor (R) cytokines IL-19, IL-20, and IL-24 are produced in both the peripheral blood and the sy
Externí odkaz:
https://doaj.org/article/10a04b9d47564c87a957b607b0b4af26
Autor:
Kasper Vadstrup, Elisabeth Douglas Galsgaard, Jens Gerwien, Marianne Kajbæk Vester-Andersen, Julie Steen Pedersen, Julie Rasmussen, Søren Neermark, Marianne Kiszka-Kanowitz, Teis Jensen, Flemming Bendtsen
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0155335 (2016)
Crohn's disease (CD) is a chronic illness demanding better therapeutics. The marketed biologics only benefit some patients or elicit diminishing effect over time. To complement the known methods in drug development and to obtain patient specific drug
Externí odkaz:
https://doaj.org/article/b9b2ab5d62134c26be2a5956bd640a67
Autor:
Bruce W Kirkham, Elena Nikiphorou, Christopher J Edwards, Mohamed Sheesh, Ewa Haladyj, Jens Gerwien, Liliana Zaremba-Pechmann, Peter C Taylor
Publikováno v:
Rheumatology. 62
Background/Aims Baricitinib, an oral selective JAK 1/2 inhibitor, is approved for treating adults with moderate-to-severe active rheumatoid arthritis (RA). This analysis aims to report the efficacy of baricitinib in patients with moderate RA at weeks
Autor:
James C. Ryan, Kasper Vadstrup, Teis Jensen, Lewis L. Lanier, Helle Jensen, Marianne K Vester-Andersen, Shih-Yu Chen, Elisabeth D. Galsgaard, Flemming Bendtsen, Jens Gerwien, Garry P. Nolan, Julie Steen Pedersen
Publikováno v:
Experimental and molecular pathology, vol 103, iss 1
Interaction between the activating NKG2D receptor on lymphocytes and its ligands MICA, MICB, and ULBP1–6 modulate T and NK cell activity and may contribute to the pathogenesis of Crohn’s disease (CD). NKG2D ligands are generally not expressed on
Autor:
Veerle Fleskens, Leonie S. Taams, Bina Menon, Megha Rajasekhar, Jens Gerwien, Gina J Walter, Hayley G. Evans, Klaus Stensgaard Frederiksen
Publikováno v:
Arthritis & Rheumatology. 68:103-116
Objective Conflicting evidence exists regarding the suppressive capacity of Treg cells in the peripheral blood (PB) of patients with rheumatoid arthritis (RA). The aim of this study was to determine whether Treg cells are intrinsically defective in R
Autor:
Thomas Rasmussen, Katarina Håkansson, Olof Grip, Sabina Janciauskiene, Jens Gerwien, Susanne T. Gren
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 12, p e0144351 (2015)
PLoS ONE, Vol 10, Iss 12, p e0144351 (2015)
Human monocytes are a heterogeneous cell population classified into three different subsets: Classical CD14++CD16-, intermediate CD14++CD16+, and non-classical CD14+CD16++ monocytes. These subsets are distinguished by their differential expression of
Autor:
Michael Brines, Johan van Beek, Anna Kirstine Larsen, Anthony Cerami, Jens Gerwien, Marcel Leist, Lars Torup, Pia Villa, Søren Christensen, Pietro Ghezzi
Publikováno v:
Journal of Cerebral Blood Flow & Metabolism. 27:552-563
Carbamylerythropoietin (CEPO) does not bind to the classical erythropoietin (EPO) receptor. Nevertheless, similarly to EPO, CEPO promotes neuroprotection on the histologic level in short-term stroke models. In the present study, we investigated wheth
Autor:
Thomas N. Sager, Alessandra Sfacteria, Marina Bianchi, Marcel Leist, Lars Torup, Søren Christensen, Serhat Erbayraktar, Jacob Nielsen, Michael Brines, Lars Østergaard Pedersen, Pekka Kallunki, Thomas Coleman, Osman Yilmaz, Giovanni Grasso, Lone Helboe, Zübeyde Erbayraktar, Pietro Ghezzi, Pia Villa, Necati Gokmen, Qiao-Wen Xie, Roberto Bianchi, Maddalena Fratelli, Carla Cerami-Hand, Costanza Savino, Jens Gerwien, Anthony Cerami, Mette Nielsen, Anna Kirstine Larsen
Publikováno v:
Science. 305:239-242
Erythropoietin (EPO) is both hematopoietic and tissue protective, putatively through interaction with different receptors. We generated receptor subtype–selective ligands allowing the separation of EPO's bioactivities at the cellular level and in a